ArticleJournal of medicinal chemistry2026

FDA Approval of the First-Ever PROTAC: Vepdegestrant (ARV-471) Marks a New Era in Targeted Protein Degradation.

Anil Kumar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.